Product Description
Butorphanol nasal spray is used to relieve moderate to severe pain. Butorphanol is in a class of medications called opioid agonist-antagonists. It works by changing the way the body senses pain. (Sourced from: https://medlineplus.gov/druginfo/meds/a601204.html)
Mechanisms of Action: OPR Antagonist,OPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Brazil | Canada | Chile | China | Colombia | India | Ireland | Korea | New Zealand | Norway | Pakistan | Philippines | Poland | Russia | South Africa | Taiwan | Ukraine | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|